Bernard Chevalier

Showing 1-20 of 36 articles

Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry

Mohamed M, Polad J, Hildick-Smith D, Bizeau O, Baisebenov R, Roffi M, Íñiguez-Romo A, Chevalier B, von Birgelen C, Roguin A, Aminian A, Angioi M, Mamas M

June 25, 2020 | 10.4244/EIJ-D-20-00361

Coronary interventions

Bioresorbable scaffolds versus everolimus-eluting metallic stents: Five years clinical outcomes of the randomised ABSORB II trial

Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrie D, Sabate M, Windecker S, Rapoza R, West N, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Serruys P

June 9, 2020 | 10.4244/EIJ-D-20-00024

Coronary interventions

Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis: The COMPARE-ABSORB Randomized Clinical Trial

Smits P, Chang C, Chevalier B, West N, Gori T, Barbato E, Tarantini G, Kocka V, Achenbach S, Dudek D, Escaned J, Włodarczak A, Abdel-Wahab M, Esposito G, Tijssen J, Morice M, Onuma Y, van Geuns R

May 26, 2020 | 10.4244/EIJ-D-19-01079

Coronary interventions

Acute and long-term relocation of minimal lumen area after bioresorbable scaffold or metallic stent implantation

Katagiri Y, Serruys P, Tenekecioglu E, Asano T, Collet C, Miyazaki Y, Katsikis A, Piek J, Wykrzykowska J, Chevalier B, Mintz G, Stone G, Onuma Y

September 20, 2019 | 10.4244/EIJ-D-18-00422

Coronary interventions

Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

Katagiri Y, Onuma Y, Asano T, Chichareon P, Collet C, Miyazaki Y, Piek J, Wykrzykowska J, Abizaid A, Ormiston J, Chevalier B, Serruys P

October 12, 2018 | 10.4244/EIJ-D-18-00301

Polymer-free drug-coated stents: workhorse or “niche horse”?

Urban P, Chevalier B

September 20, 2018 | 10.4244/EIJV14I7A128

Stents and scaffolds

Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

Chevalier B, Cequier A, Dudek D, Haude M, Carrié D, Sabate M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Onuma Y, Serruys P

January 19, 2018 | 10.4244/EIJ-D-17-00873

Coronary interventions

Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?

Roy A, Chevalier B, Lefèvre T, Louvard Y, Segurado R, Sawaya F, Spaziano M, Neylon A, Serruys P, Dawkins K, Kappetein AP, Mohr F, Colombo A, Feldman T, Morice M

September 20, 2017 | 10.4244/EIJ-D-16-00991

Coronary interventions

Chronic total coronary occlusion treated by percutaneous coronary intervention: long-term outcome in patients with and without diabetes

Sanguineti F, Garot P, O’Connor S, Watanabe Y, Spaziano M, Lefèvre T, Hovasse T, Benamer H, Unterseeh T, Chevalier B, Morice M, Louvard Y

February 3, 2017 | 10.4244/EIJ-D-15-00278

Coronary interventions

Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial

Chevalier B, Onuma Y, Van Boven A, Piek J, Sabate M, Helqvist S, Baumbach A, Smits P, Kumar R, Wasungu L, Serruys P

October 20, 2016 | 10.4244/EIJY16M08_01

Interventions for valvular disease

Patient-specific image-based computer simulation for the prediction of valve morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards SAPIEN valve

Schultz C, Rodriguez-Olivares R, Bosmans J, Lefèvre T, De Santis G, Bruining N, Collas V, Dezutter T, Bosmans B, Rahhab Z, Faquir N, Watanabe Y, Segers P, Verhegghe B, Chevalier B, Van Mieghem N, De Beule M, Mortier P, de Jaegere P

January 20, 2016 | 10.4244/EIJV11I9A212

Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data

Bourantas C, Serruys P, Nakatani S, Zhang Y-J, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns R, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia H

November 20, 2015 | 10.4244/EIJY14M10_06

Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P

September 22, 2015 | 10.4244/EIJY14M12_13

Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold

Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Perin M, Seth A, Botelho R, Serruys P

June 19, 2015 | 10.4244/EIJY15M05_06

Coronary interventions

The future of BRS in bifurcations

Kraak R, Grundeken M.J, Onuma Y, Tu S, Wykrzykowska J, Chevalier B, Ormiston J, Serruys P

May 19, 2015 | 10.4244/EIJV11SVA45

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled

Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P

April 20, 2015 | 10.4244/EIJV10I12A243

Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial

Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P

March 20, 2015 | 10.4244/EIJY14M04_11

Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J

March 20, 2014 | 10.4244/EIJV9I11A217

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P

October 25, 2013 | 10.4244/EIJV9I6A115

The Colibri heart valve: theory and practice in the achievement of a low-profile, pre-mounted, pre-packaged TAVI valve

Fish R, Paniagua D, Urena P, Chevalier B

September 15, 2013 | 10.4244/EIJV9SSA23

Latest news

NEW ISSUE

PCR e-Course; LM interventions; FFR and STEMI, the EAPCI and COVID-19; TMVR

June 25, 2020

NEW

Ahead of print: EAPCI Core Curriculum for PCI (2020)

July 7, 2020

Editorial

IVUS guidance during left main PCI: not if, but when and how

Akiko Maehara

July 8, 2020

NEW

Ahead of print: EAPCI Expert Consensus Document: Ischaemia with non-obstructive coronary arteries

V. Kunadian et al

July 6, 2020

Editorial

Left main PCI: are we giving the kiss the attention it deserves?

July 8, 2020

Find the latest trials:

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

July 1, 2020

JAA

This Week's JAA's: CULPRIT-SHOCK substudy, Coronary Microcatheter Complications...

Bernard Chevalier

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke